DeFrancesco Lisa 4

What Happened
Lisa DeFrancesco, SVP of Investor Relations & Corporate Communications at Lexicon Pharmaceuticals (LXRX), was granted two awards on February 12, 2026 totaling 643,830 restricted stock units (257,530 and 386,300). The awards are reported as derivative grants (code A) at $0.00 per unit — these are RSUs (contingent rights to receive shares upon vesting), not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-12 (reported on Form 4 filed 2026-02-17).
• Grants: 257,530 RSUs and 386,300 RSUs (total 643,830 RSUs); price reported $0.00 (award/derivative).
• Shares owned after transaction: Not disclosed in the provided filing.
• Vesting (footnote F1–F2): Each RSU equals a contingent right to one share (F1). RSUs vest 1/3 of the award on February 28 of each of the three years following the year of grant (F2).
• Other footnote (F3): Describes a standard option vesting schedule (25% after 1 year, then monthly 1/48th); this relates to options generally and is not the RSU grant mechanism here.
• Filing timeliness: Form filed 5 days after the transaction date; Form 4s are normally due within two business days, so this filing appears later than standard—late filings can draw SEC attention and should be noted by investors.
• Tax withholding / shares withheld: None reported in the provided data.

Context
RSU awards are compensation — they do not involve an immediate cash outlay or sale and only convert to stock as they vest. Such grants are common for executive and senior employee compensation and are not by themselves a direct bullish or bearish signal about near-term stock moves.